期刊
LEUKEMIA
卷 28, 期 2, 页码 391-397出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/leu.2013.217
关键词
multiple myeloma; multiparameter flow cytometry; ASO RQ-PCR; minimal residual disease
资金
- Spanish 'Instituto de Salud Carlos III (ISCIII)' [PS09/01450, PI12/02311]
- Red Tematica de Investigacion Cooperativa en Cancer (RTICC), Spanish Ministry of Economy and Competitiveness [RD12/0036/0069]
- European Regional Development Fund (ERDF) 'Una manera de hacer Europa' [RD12/0036/0058]
- 'Consejeria de Educacion de la Junta de Castilla y Leon' [HUS412A12-1]
- Asociacion Espanola Contra el Cancer (AECC) [GCB-120981SAN]
- SEHH (Sociedad Espanola de Hematologia y Hemoterapia)
We have analyzed the applicability, sensitivity and prognostic value of allele-specific oligonucleotide real-time quantitative PCR (ASO RQ-PCR) as a method for minimal residual disease (MRD) assessment in patients with multiple myeloma (MM), comparing the results with those of multiparameter flow cytometry (MFC). A total of 170 patients enrolled in three consecutive Spanish trials achieving at least partial response after treatment were included. Lack of clonality detection (n = 31), unsuccessful sequencing (n = 17) and suboptimal ASO performance (n = 51) limited the applicability of PCR to 42% of cases. MRD was finally investigated in 103 patients (including 32 previously studied) with persistent disease identified by PCR and MFC in 54% and 46% of cases, respectively. A significant correlation in MRD quantitation by both the techniques was noted (r = 0.881, P<0.001), being reflective of treatment intensity. Patients with < 10(-4) residual tumor cells showed longer progression-free survival (PFS) compared with the rest (not reached (NR) vs 31 months, P = 0.002), with similar results observed with MFC. Among complete responders (n = 62), PCR discriminated two risk groups with different PFS (49 vs 26 months, P = 0.001) and overall survival (NR vs 60 months, P = 0.008). Thus, although less applicable than MFC, ASO RQ-PCR is a powerful technique to assess treatment efficacy and risk stratification in MM.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据